MarketMoodz
AstraZeneca Advances Rare-Bone Drug as Enhertu Wins EU Tumor‑Agnostic Label
AstraZeneca reported positive Phase 3 MULBERRY results for efzimfotase alfa (ALXN1850) in hypophosphatasia, showing a median Radiographic Global Impression of Change (RGI‑C) score of 1.67 at week 25 versus placebo (p=0.0003) and the trial’s primary endpoint met. Separately, Enhertu (trastuzumab deruxtecan) received EU tumor‑agnostic approval for adults with unresectable or metastatic HER2‑positive solid tumors, triggering a $25 million milestone payment from AstraZeneca to Daiichi Sankyo.
Key Takeaways
- Phase 3 MULBERRY met its primary endpoint for efzimfotase alfa in hypophosphatasia; median RGI‑C 1.67 at week 25 versus placebo (p=0.0003).
- Key secondary endpoints showed improvement in Rickets Severity Score and measures of physical function and quality of life versus placebo.
- Pooled and switch data (MULBERRY, HICKORY, CHESTNUT) report fewer injection‑site reactions versus Strensiq and comparable adverse‑event rates on switching.
- Enhertu earned EU tumor‑agnostic approval based on DESTINY program data, with objective response rates of roughly 46.9%–52.9% across trials.
- AstraZeneca will pay a $25 million milestone to Daiichi Sankyo tied to the tumor‑agnostic indication.
People Involved
- No specific individuals mentioned
Entities Involved
- AstraZeneca PLC (AZN)Developer/sponsor of efzimfotase alfa and commercial partner for Enhertu
- Daiichi SankyoCo‑developer of Enhertu and counterparty for milestone payment
- European CommissionRegulatory authority that granted the EU tumor‑agnostic approval
MarketMoodz Analysis
For investors, these updates spotlight two near‑term value drivers: a potential rare‑disease launch and expanded oncology revenue. MULBERRY’s primary‑endpoint win and secondary signals in rickets severity, walking distance and pediatric quality‑of‑life measures strengthen efzimfotase alfa’s case as a commercial alternative to existing therapy for hypophosphatasia, particularly if tolerability (notably fewer injection‑site reactions in pooled analyses) holds up in full datasets. Rare pediatric therapies can command premium pricing and steady uptake in niche populations, so regulatory approvals and favorable reimbursement would translate to outsized per‑patient economics despite a small patient pool.
Enhertu’s EU tumor‑agnostic label broadens AstraZeneca’s addressable oncology market beyond breast cancer into multiple HER2‑positive solid tumors; objective response rates in the mid‑40s to low‑50s percent range across DESTINY trials are strong in heavily pretreated cohorts and support commercial uptake. The $25 million milestone to Daiichi Sankyo is modest relative to potential incremental sales, but it signals partner economics investors should model into forecasts. Next catalysts: primary publications or regulatory filings confirming exact numerical results, EMA/European Commission labeling details, pricing and reimbursement decisions in major EU markets, and post‑market safety/readouts — any of which will materially affect revenue timing and upside.
Source: Original Article